Shots:
- The EMA’s CHMP has granted positive opinion to Kavigale for the prevention of COVID-19 in immunocompromised individuals (≥12yrs.). It was reviewed under the EMA’s accelerated pathway
- Kavigale consists of an antiviral human IgG1 mAb, sipavibart, as its API that offers passive protection against SARS-CoV-2 by targeting the spike protein’s receptor-binding domain
- Sipavibart was discovered by RQ Bio and The University of Oxford. It was licensed to AstraZeneca as per an agreement signed in May 2022
Ref: Globenewswire | Image: AstraZeneca & RQ Biotechnology
Related News:- AstraZeneca’s Calquence (Acalabrutinib) Plus Chemoimmunotherapy Secures the US FDA’s Approval for Mantle Cell Lymphoma (MCL)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
